Cargando…
Machine learning methods for accurately predicting survival and guiding treatment in stage I and II hepatocellular carcinoma
Accurately predicting survival in patients with early hepatocellular carcinoma (HCC) is essential for making informed decisions about treatment and prognosis. Herein, we have developed a machine learning (ML) model that can predict patient survival and guide treatment decisions. We obtained patient...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10637529/ https://www.ncbi.nlm.nih.gov/pubmed/37960763 http://dx.doi.org/10.1097/MD.0000000000035892 |
_version_ | 1785146517381709824 |
---|---|
author | Li, Xianguo Bao, Haijun Shi, Yongping Zhu, Wenzhong Peng, Zuojie Yan, Lizhao Chen, Jinhuang Shu, Xiaogang |
author_facet | Li, Xianguo Bao, Haijun Shi, Yongping Zhu, Wenzhong Peng, Zuojie Yan, Lizhao Chen, Jinhuang Shu, Xiaogang |
author_sort | Li, Xianguo |
collection | PubMed |
description | Accurately predicting survival in patients with early hepatocellular carcinoma (HCC) is essential for making informed decisions about treatment and prognosis. Herein, we have developed a machine learning (ML) model that can predict patient survival and guide treatment decisions. We obtained patient demographic information, tumor characteristics, and treatment details from the SEER database. To analyze the data, we employed a Cox proportional hazards (CoxPH) model as well as 3 ML algorithms: neural network multitask logistic regression (N-MLTR), DeepSurv, and random survival forest (RSF). Our evaluation relied on the concordance index (C-index) and Integrated Brier Score (IBS). Additionally, we provided personalized treatment recommendations regarding surgery and chemotherapy choices and validated models’ efficacy. A total of 1136 patients with early-stage (I, II) hepatocellular carcinoma (HCC) who underwent liver resection or transplantation were randomly divided into training and validation cohorts at a ratio of 3:7. Feature selection was conducted using Cox regression analyses. The ML models (NMLTR: C-index = 0.6793; DeepSurv: C-index = 0.7028; RSF: C-index = 0.6890) showed better discrimination in predicting survival than the standard CoxPH model (C-index = 0.6696). Patients who received recommended treatments had higher survival rates than those who received unrecommended treatments. ML-based surgery treatment recommendations yielded higher hazard ratios (HRs): NMTLR HR = 0.36 (95% CI: 0.25–0.51, P < .001), DeepSurv HR = 0.34 (95% CI: 0.24–0.49, P < .001), and RSF HR = 0.37 (95% CI: 0.26–0.52, P = <.001). Chemotherapy treatment recommendations were associated with significantly improved survival for DeepSurv (HR: 0.57; 95% CI: 0.4–0.82, P = .002) and RSF (HR: 0.66; 95% CI: 0.46–0.94, P = .020). The ML survival model has the potential to benefit prognostic evaluation and treatment of HCC. This novel analytical approach could provide reliable information on individual survival and treatment recommendations. |
format | Online Article Text |
id | pubmed-10637529 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-106375292023-11-15 Machine learning methods for accurately predicting survival and guiding treatment in stage I and II hepatocellular carcinoma Li, Xianguo Bao, Haijun Shi, Yongping Zhu, Wenzhong Peng, Zuojie Yan, Lizhao Chen, Jinhuang Shu, Xiaogang Medicine (Baltimore) 4500 Accurately predicting survival in patients with early hepatocellular carcinoma (HCC) is essential for making informed decisions about treatment and prognosis. Herein, we have developed a machine learning (ML) model that can predict patient survival and guide treatment decisions. We obtained patient demographic information, tumor characteristics, and treatment details from the SEER database. To analyze the data, we employed a Cox proportional hazards (CoxPH) model as well as 3 ML algorithms: neural network multitask logistic regression (N-MLTR), DeepSurv, and random survival forest (RSF). Our evaluation relied on the concordance index (C-index) and Integrated Brier Score (IBS). Additionally, we provided personalized treatment recommendations regarding surgery and chemotherapy choices and validated models’ efficacy. A total of 1136 patients with early-stage (I, II) hepatocellular carcinoma (HCC) who underwent liver resection or transplantation were randomly divided into training and validation cohorts at a ratio of 3:7. Feature selection was conducted using Cox regression analyses. The ML models (NMLTR: C-index = 0.6793; DeepSurv: C-index = 0.7028; RSF: C-index = 0.6890) showed better discrimination in predicting survival than the standard CoxPH model (C-index = 0.6696). Patients who received recommended treatments had higher survival rates than those who received unrecommended treatments. ML-based surgery treatment recommendations yielded higher hazard ratios (HRs): NMTLR HR = 0.36 (95% CI: 0.25–0.51, P < .001), DeepSurv HR = 0.34 (95% CI: 0.24–0.49, P < .001), and RSF HR = 0.37 (95% CI: 0.26–0.52, P = <.001). Chemotherapy treatment recommendations were associated with significantly improved survival for DeepSurv (HR: 0.57; 95% CI: 0.4–0.82, P = .002) and RSF (HR: 0.66; 95% CI: 0.46–0.94, P = .020). The ML survival model has the potential to benefit prognostic evaluation and treatment of HCC. This novel analytical approach could provide reliable information on individual survival and treatment recommendations. Lippincott Williams & Wilkins 2023-11-10 /pmc/articles/PMC10637529/ /pubmed/37960763 http://dx.doi.org/10.1097/MD.0000000000035892 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC) (https://creativecommons.org/licenses/by-nc/4.0/) , where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. |
spellingShingle | 4500 Li, Xianguo Bao, Haijun Shi, Yongping Zhu, Wenzhong Peng, Zuojie Yan, Lizhao Chen, Jinhuang Shu, Xiaogang Machine learning methods for accurately predicting survival and guiding treatment in stage I and II hepatocellular carcinoma |
title | Machine learning methods for accurately predicting survival and guiding treatment in stage I and II hepatocellular carcinoma |
title_full | Machine learning methods for accurately predicting survival and guiding treatment in stage I and II hepatocellular carcinoma |
title_fullStr | Machine learning methods for accurately predicting survival and guiding treatment in stage I and II hepatocellular carcinoma |
title_full_unstemmed | Machine learning methods for accurately predicting survival and guiding treatment in stage I and II hepatocellular carcinoma |
title_short | Machine learning methods for accurately predicting survival and guiding treatment in stage I and II hepatocellular carcinoma |
title_sort | machine learning methods for accurately predicting survival and guiding treatment in stage i and ii hepatocellular carcinoma |
topic | 4500 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10637529/ https://www.ncbi.nlm.nih.gov/pubmed/37960763 http://dx.doi.org/10.1097/MD.0000000000035892 |
work_keys_str_mv | AT lixianguo machinelearningmethodsforaccuratelypredictingsurvivalandguidingtreatmentinstageiandiihepatocellularcarcinoma AT baohaijun machinelearningmethodsforaccuratelypredictingsurvivalandguidingtreatmentinstageiandiihepatocellularcarcinoma AT shiyongping machinelearningmethodsforaccuratelypredictingsurvivalandguidingtreatmentinstageiandiihepatocellularcarcinoma AT zhuwenzhong machinelearningmethodsforaccuratelypredictingsurvivalandguidingtreatmentinstageiandiihepatocellularcarcinoma AT pengzuojie machinelearningmethodsforaccuratelypredictingsurvivalandguidingtreatmentinstageiandiihepatocellularcarcinoma AT yanlizhao machinelearningmethodsforaccuratelypredictingsurvivalandguidingtreatmentinstageiandiihepatocellularcarcinoma AT chenjinhuang machinelearningmethodsforaccuratelypredictingsurvivalandguidingtreatmentinstageiandiihepatocellularcarcinoma AT shuxiaogang machinelearningmethodsforaccuratelypredictingsurvivalandguidingtreatmentinstageiandiihepatocellularcarcinoma |